SCHEMBL441773

SCHEMBL441773

NN=C(NN)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAOA P21397 4/20 0.39
MAOB P27338 4/20 0.39
CYP3A4 P08684 3/20 0.37
TDP1 Q9NUW8 3/20 0.37
MAPT P10636 2/20 0.37
BLM P54132 2/20 0.37
TSHR P16473 2/20 0.37
CYP2C19 P33261 2/20 0.37
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
F12 P00748 1/20 0.37
F7 P08709 1/20 0.37
F3 P13726 1/20 0.37
PKM P14618 1/20 0.37
POLB P06746 1/20 0.37
PARP1 P09874 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945465 1.00 NOS1 (0.40) NOS1MEN1KMT2AMAOAMAOB
SCHEMBL3960842 0.81 GAA (0.43) NOS1MEN1KMT2AMAOAMAOB
SCHEMBL23118889 0.80 TSHR (0.50) TSHRCYP2C19F2SMN1; SMN2CES1
SCHEMBL15102612 0.79 GLA (0.42) MEN1KMT2ACYP3A4TDP1MAPT
SCHEMBL20777964 0.79 MASP2 (0.39) MEN1KMT2ACYP3A4TDP1MAPT
SCHEMBL5262398 0.79 GLA (0.42) MEN1KMT2ACYP3A4TDP1MAPT
SCHEMBL20364008 0.78 AKR1C3 (0.53) MEN1KMT2AMAOBF2F10
SCHEMBL21339902 0.77 OGG1 (0.52) NOS1MAPTF2POLBRECQL
SCHEMBL4959117 0.77 NOS1 (0.57) NOS1MEN1KMT2AMAOAMAOB
SCHEMBL8443723 0.76 MAOA (0.39) MEN1KMT2AMAOAMAOBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1576093-A4 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS INC (US) 2009-07-08 EP claimed
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin DYNAMIS THERAPEUTICS, INC. 2007-03-22 US claimed
EP-1753861-A2 FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN Dynamis Therapeutics, Inc. (US) 2007-02-21 EP claimed
EP-1576093-A2 3-DEOXYGLUCOSONE AND SKIN Dynamis Therapeutics, Inc. (US) 2005-09-21 EP claimed
WO-2005079463-A2 FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN DYNAMIS THERAPEUTICS, INC. (US) 2005-09-01 WO claimed
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) DYNAMIS THERAPEUTICS, INC. 2005-07-21 US claimed
US-20030219440-A1 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. 2003-11-27 US claimed
WO-2003089601-A2 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS, INC. (US) 2003-10-30 WO claimed
US-9758666-B2 Oxygen-absorbing resin composition and oxygen-absorbing multilayer body using the same MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2017-09-12 US disclosed
US-9725562-B2 Modified diene polymer, method for producing same, rubber composition, and pneumatic tire TOYO TIRE & RUBBER CO., LTD. (JP) 2017-08-08 US disclosed
EP-2894194-B1 OXYGEN-ABSORBING RESIN COMPOSITION AND OXYGEN-ABSORBING MULTILAYER BODY USING SAME MITSUBISHI GAS CHEMICAL CO (JP) 2017-01-11 EP disclosed
CN-104603195-B Oxygen-absorbing resin composition and the oxygen uptake polylayer forest using it 三菱瓦斯化学株式会社 2016-09-21 CN disclosed
US-20150353690-A1 MODIFIED DIENE POLYMER, METHOD FOR PRODUCING SAME, RUBBER COMPOSITION, AND PNEUMATIC TIRE TOYO TIRE & RUBBER CO., LTD. (JP) 2015-12-10 US disclosed
US-20150203678-A1 OXYGEN-ABSORBING RESIN COMPOSITION AND OXYGEN-ABSORBING MULTILAYER BODY USING THE SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2015-07-23 US disclosed
EP-1175155-A1 METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF FOX CHASE CANCER CENTER (US) 2002-01-30 EP disclosed
US-6221914-B1 ANTIINFLAMMATORY AGENTS ARRAY BIOPHARMA INC. 2001-04-24 US disclosed
WO-2000062626-A1 METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF FOX CHASE CANCER CENTER (US) 2000-10-26 WO disclosed
WO-1999024395-A1 COMPOUNDS WHICH INHIBIT TRYPTASE ACTIVITY ARRAY BIOPHARMA, INC. (US) 1999-05-20 WO disclosed
US-5262152-A Aging resistance, inhibiting glycosylation of proteins THE ROCKEFELLER UNIVERSITY (US) 1993-11-16 US disclosed
US-5130337-A Aging of proteins by reaction with glucose or other reducing sugar THE ROCKEFELLER UNIVERSITY (US) 1992-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin FN3K, PDXK, COLGALT1 NOS1 2488/4885MEN1 1069/4885KMT2A 2468/4885
US-20030219440-A1 3-deoxyglucosone and skin DPM1, G6PD, UGGT1 NOS1 2487/4885MEN1 1559/4885KMT2A 3495/4885
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) AGER, GLA, GALE NOS1 515/4885MEN1 3627/4885KMT2A 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.